Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Route of Administration
3.3. Snippet by Drug Class
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing FDA approvals of IBD drugs
4.1.2. Restraints
4.1.2.1. The expiration of patents for certain branded IBD drugs
4.1.3. Opportunity
4.1.3.1. Research and development of new therapies
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Crohn’s Disease*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ulcerative colitis
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral Route*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Rectal Route
9.4. Subcutaneous Route
9.5. Intravenous Route
10. By Drug Class
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.1.2. Market Attractiveness Index, By Drug Class
10.2. Aminosalicylates*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Corticosteroids
10.4. TNF inhibitors
10.5. IL inhibitors
10.6. Anti-integrin
10.7. JAK inhibitors
10.8. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. The U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. The U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. Brazil
12.4.7.2. Argentina
12.4.7.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. China
12.5.7.2. India
12.5.7.3. Japan
12.5.7.4. Australia
12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. AbbVie Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Takeda Pharmaceutical Company Limited
14.3. Pfizer Inc
14.4. Biogen
14.5. Novartis AG
14.6. Eli Lilly Company
14.7. Merck & Co., Inc
14.8. Johnson & Johnson
14.9. Biocon Ltd.
14.10. Sanofi
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us